HRT Financial’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

HRT Financial’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50,326	Closed	-$302K	–	3628
2022 Q4	$302K	Buy	+50,326	New	+$275K	﹤0.01%	1720
2021 Q2	–	Sell	-194,242	Closed	-$565K	–	3881
2021 Q1	$565K	Buy	194,242 +61,683	+47%	+$201K	0.01%	1675
2020 Q4	$426K	Buy	+132,559	New	+$441K	0.01%	1113
2020 Q3	–	Sell	-19,710	Closed	-$22K	–	2591
2020 Q2	$22K	Buy	+19,710	New	+$20.8K	﹤0.01%	1419

Other funds holding CTIC

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

HRT Financial's CTIC Position: Q1 2023 in Review

HRT Financial sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2023, closing a stake of 50,326 shares — an estimated $302K sold.

HRT Financial first reported a position in CTIC in Q2 2020 and held it in 4 quarters. The position peaked at $565K in Q1 2021. 133 funds tracked by Wall St. Rank hold CTIC as of Q1 2023.

HRT Financial reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2023 after selling out during the quarter.
HRT Financial sold 50,326 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2023, an estimated $302K.
HRT Financial first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2020 and held it in 4 quarters.
HRT Financial's CTI BioPharma Corp. (DE) Common Stock position peaked at $565K in Q1 2021.
133 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2023.

Based on HRT Financial's 13F filing for Q1 2023, filed 12 May 2023.